AADC Deficiency Gene Therapy: Kebilidi Offers Hope for Children With Rare Neurological Disorder

What Is AADC Deficiency and Why Is It So Devastating?

Aromatic L-amino acid decarboxylase (AADC) deficiency is caused by mutations in the DDC gene, which encodes an enzyme essential for converting precursors into the neurotransmitters dopamine, serotonin, norepinephrine, and epinephrine. Without functional AADC, infants typically present within the first year of life with severe hypotonia, developmental delay, oculogyric crises, and autonomic instability including temperature dysregulation and excessive sweating. Many affected children never achieve head control, sitting, or speech, and life expectancy is significantly shortened in severe cases.

The disorder is classified as ultra-rare, with only several hundred patients identified worldwide, according to the National Organization for Rare Disorders. Because symptoms overlap with cerebral palsy, epilepsy, and mitochondrial disease, diagnosis is frequently delayed — often for years — until cerebrospinal fluid neurotransmitter analysis and genetic testing confirm the condition. Standard supportive care with dopamine agonists, MAO inhibitors, and pyridoxine offers only modest symptomatic benefit for most patients.

How Does Kebilidi Gene Therapy Work?

Kebilidi (eladocagene exuparvovec-tneq), developed by PTC Therapeutics, became the first FDA-approved gene therapy administered directly into the brain when it received approval in November 2024. The therapy was previously authorized in the European Union in 2022 under the brand name Upstaza. Treatment involves a specialized neurosurgical procedure in which the viral vector is infused bilaterally into the putamen — a region of the basal ganglia central to motor control — through stereotactically guided cannulas.

Clinical trial data submitted to the FDA showed meaningful gains in motor milestones including head control, sitting, and in some cases standing or walking, along with reductions in oculogyric crises. Because the procedure requires pediatric neurosurgical expertise, intraoperative MRI guidance, and specialized postoperative care, only a small number of centers of excellence — including Texas Children's Hospital and a handful of other pediatric academic medical centers — are currently qualified to administer the therapy.

What Does This Mean for Pediatric Neurology Going Forward?

The approval represents a significant milestone for the gene therapy field, demonstrating that viral vectors can be safely and effectively delivered to deep brain structures in young children. Similar approaches are now being evaluated in clinical trials for other rare pediatric neurological conditions, including certain leukodystrophies, Batten disease variants, and other neurotransmitter disorders. The FDA has signaled continued support for ultra-rare disease gene therapies through regenerative medicine advanced therapy (RMAT) designations.

Challenges remain substantial. Newborn screening for AADC deficiency is not yet widespread, meaning many children are diagnosed only after significant neurological damage has occurred. Access and cost are also pressing concerns: like other one-time gene therapies, Kebilidi carries a list price in the millions of dollars, raising difficult questions for insurers and health systems. Patient advocacy organizations and specialty pediatric centers are working to expand newborn screening, streamline referral pathways, and ensure equitable access for eligible families.